Adding pembrolizumab to weekly paclitaxel, with or without bevacizumab, improved PFS in patients with platinum-resistant, recurrent ovarian cancer in a phase 3 trial.

Adding EV and pembrolizumab to surgical treatment can improve outcomes in MIBC patients who are ineligible for cisplatin, data suggest.

Administering durvalumab before and after CRT did not provide a benefit over CRT alone in a phase 3 trial of patients with intermediate- and high-risk oropharyngeal cancer.

Adding nimotuzumab to post-surgery adjuvant cisplatin-based chemoradiotherapy does not improve survival outcomes in patients with HNSCC.

Tiragolumab plus atezolizumab does not improve survival compared to durvalumab in locally advanced, unresectable, stage 3 NSCLC.

Data from a phase 1/2 study support the use of sevabertinib in patients with HER2-mutated NSCLC, an investigator says.

This article was originally published on Stateline. In a clear rebuke of recent federal health policy, 15 Democratic governors announced Wednesday they’ve formed a public health alliance that breaks ...

For patients with advanced or metastatic RCC, fruquintinib plus sintilimab improves PFS compared to investigator’s choice of axilitinib or everolimus.

In TNBC, pembrolizumab at a tenth of the current standard dose, plus chemotherapy, increased pCR compared to chemotherapy alone.

Adding durvalumab to induction and maintenance with Bacillus Calmette–Guérin (BCG) can improve disease-free survival in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer, data ...

Regorafenib plus nivolumab did not improve survival over chemotherapy in patients with previously treated gastric/GEJ cancer.

Adding abemaciclib to endocrine therapy improved overall survival in patients with HR-positive, HER2-negative, node-positive, high-risk early breast cancer.